- Macy's Loss Beats Estimates, But Shares Fall on Outlook
- AIG CEO Ready to Quit over Pay Constraints: Report
- Pay Caps Make it Hard for GM to Hire Execs: Whitacre
- Tresury Report Says $209 Billion Left in TARP Funds

- Unemployment May Cause Loan Defaults in US: Zoellick
- UPS Sees 2010 Volume Growth, Higher Rates
- Sen. Dodd: Fed Should Return To 'Core Functions'

- Just 1 in 20 Plan to Buy a Home Next Year: Survey
- Website Launches That Gives Free Access to Concerts
- Commercial Real Estate Best Place For Money: Strategist
- Schork Oil Outlook: Nat Gas Bulls Didn’t Stand A Chance
- Enterprise Tech Companies to Focus On: Portfolio Manager
- Agassi Book Buzz Paying Off Early
- Cadillac Converj Smart Extension of Volt
- This Chemical Company Will Rally into 2010: Trader
- 3 Safe Investments That Let You ‘Sleep Better:’ Strategist
- Beware of 'Trampling Effect' When Market Tops: Manager
- Gold Heading to $1150: Art Hogan
- Allstate elects new director to board
- Oregon tax activist says opponents lied about him
- Businesses fear Europe's recovery to remain timid
- Carnahan excited, concerned about health care bill
- Kan. education board laments cuts in school funds
- Denver man accused in $12.5 million Ponzi scheme
- PSE&G cleared for additional NJ solar projects
- DeVry increases annual dividend by 25 percent
- State's Oct. revenue collections below projections
WASHINGTON - Federal health officials are adding their sternest warning to a heartburn drug from Wyeth that has been linked to muscle spasms.
The Food and Drug Administration said Wyeth's pill Reglan has been shown to cause spasms and tics when used for long periods of time or at high doses. The agency is requiring both Wyeth and generic drugmakers to add a black box warning, the most serious type available, to their products.
Manufacturers also will be required to distribute medication safety guides to patients.
The drug's current labeling already mentions risks of developing the spasms, called dykinesia, but the agency's action Thursday elevates the warning to the top of the label. Reglan, known generically as metoclopramide, comes in a variety forms, including injections and edible syrups. The drug works by speeding up the muscles used in digestion and relieving painful stomach acid reflux.
More than 2 million U.S. patients use the drugs, according to the FDA.
"The chronic use of metoclopramide therapy should be avoided in all but rare vases where the benefit is believed to outweigh the risk," said Dr. Janet Woodcock, director of FDA's drug center.
Regulators said patients who face the greatest risks include the elderly, especially women, and those who have been taking the drug for more than three months.
The agency based its decision on recently published studies suggesting metoclopramide is the leading cause of pharmaceutical-related movement disorders.
Wyeth representatives had no immediate comment Thursday afternoon. The Madison, N.J.-based company recently was acquired in a $68 billion deal by Pfizer, the world's largest drugmaker.
- Bernard and Ruth Madoff's personal possessions will be auctioned this weekend. Click ahead to see.
- If you are lucky enough to have money and the time, this is a great time to see America, says CNBC's Jane Wells.
- Vote and suggest your own, and remember--there's a fine line between a hero and a zero.
- How the Lord’s Prayer would read if Goldman Sachs’ Lloyd Blankfein were substituted for you-know-who.
- With 123 years of history, slogans and commercials, Coca-Cola is the most recognized brand on earth.
- The opening of a virtual pet store in “World of Warcraft” could prove a cash bonanza for Activision-Blizzard.









